Cyclophosphamide/Prednisone/ThalidomideLack of efficacy following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2016卷 / 1期

关键词：

D O I：

10.1007/s40278-024-62649-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：156 / 156

相关论文

共 50 条

[21] AntibacterialsLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1920 (1) : 43 - 43
[22] Multiple drugsNausea and lack of efficacy following off-label use
Reactions Weekly, 2024, 2013 (1) : 306 - 306
[23] RituximabLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1905 (1) : 444 - 444
[24] FavipiravirLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1945 (1) : 254 - 254
[25] AmiodaroneLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1969 (1) : 29 - 29
[26] VenetoclaxLack of efficacy following off-label use: case report
Reactions Weekly, 2024, 2039 (1) : 550 - 550
[27] FluoxetineLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1939 (1) : 219 - 219
[28] ChlorhexidineLack of efficacy following off-label use: case report
Reactions Weekly, 2025, 2055 (1) : 96 - 96
[29] AtomoxetineVarious toxicities and lack of efficacy following off-label use
Reactions Weekly, 2024, 2000 (1) : 61 - 61
[30] HydroxychloroquineLack of efficacy following an off-label use: case report
Reactions Weekly, 2021, 1858 (1) : 182 - 182

← 1 2 3 4 5 →